Leina Verrier

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.

Cooley advised Talkiatry, a top provider of high-quality, in-network psychiatric care, on its $130 million equity and debt financing round.

Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners.